BeOne Medicines (6160.HK) Earnings Analysis

BeOne Medicines (6160.HK) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it missed with EPS 0.3611 HKD vs 0.746 HKD est (-51.6%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 67.74.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 6160.HK next report earnings?

No confirmed upcoming earnings date is currently scheduled for 6160.HK. This page updates as the calendar is published.

6160.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-260.3611 HKD0.746 HKD-51.6%Miss
2025-11-060.664 HKD0.544 HKD+22.1%Beat
2025-02-24-0.85406 HKD-0.60604 HKD-40.9%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

6160.HK valuation and analyst view

Trailing P/E67.74
Trailing EPS0.35515 HKD
Price / book7.49
Dividend yield0.00%
Market cap265.03B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is BeOne Medicines (6160.HK)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 6160.HK. This page updates as the calendar is published.

Did 6160.HK beat earnings last quarter?

In its 2026-02-26 report, 6160.HK posted EPS of 0.3611 HKD versus a 0.746 HKD estimate — a miss of 51.6%.

What is 6160.HK's earnings track record?

Over the last 3 reported quarters with consensus data, 6160.HK beat estimates 1 times (33%).

What is 6160.HK's current P/E ratio and EPS?

6160.HK trades at a trailing P/E of 67.74 on trailing EPS of 0.35514615333404503 HKD.

What do analysts rate 6160.HK?

6160.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.